HCV Archives – Page 4 of 21 – Treatment Action Group

Whose Intellect? Whose Property? A Blueprint for Bringing Down the Pharma IP House of Cards

December 7, 2018
Chad Cipiti

By JD Davids, TAGline Guest Editor and Suraj Madoori, U.S. and Global Health Policy Director, TAG As the Trump administration makes noise about the high price of pharmaceuticals while doubling down on its commitment to “protect the engine of American…

Hepatitis Cure, Sofosbuvir, Turns 5 Years Old: The Vast Majority of People Still Have Not Been Treated

December 6, 2018
Chad Cipiti

Advocates scandalized that Gilead's hepatitis C profits have raked in US$25.8 billion, which could have treated everyone while still earning US$16 billions in profits.

2018 TAG Update

December 4, 2018
Chad Cipiti

I want to thank all of you for the support that enabled the successes TAG achieved this past year. Despite a challenging political climate and continued attacks against those living with or at risk of contracting HIV, tuberculosis (TB), or…

Right to Science Submission – October, 2018

October 16, 2018
Chad Cipiti

The right to enjoy the benefits of scientific progress and its applications is a fundamental human right and one of the central pillars of TAG's advocacy to promote TB research and access to its benefits. The right is enshrined in Article 27 of the Universal Declaration of Human Rights and further articulated in Article 15 of the International Covenant on Economic, Social, and Cultural Rights (ICESCR).

The HCV Diagnostics Pipeline

October 10, 2018
Chad Cipiti

July 2018 by Bryn Gay Simpler Rapid, Point-of-Care Hepatitis C Diagnostics: Are We There Yet?1 To increase treatment rates and make a dent in the epidemic by 2030, countries need to scale up access to affordable, simple, rapid diagnostics, ensuring…

The HCV Treatment Pipeline

October 10, 2018
Chad Cipiti

July 2018 Annette Gaudino HCV TREATMENT PIPELINE: THE DEFERRED DREAM OF TREATMENT FOR ALL Generic combinations of direct-acting antivirals (DAAs), including sofosbuvir/daclatasvir show bioequivalence compared to originators with equivalent sustained virological responses (SVR). Both sofosbuvir/daclatasvir and sofosbuvir/ravidasvir demonstrate SVR rates…

TAG Applauds New York Governor for Committing to Statewide Hepatitis C Elimination Task Force, Action Puts NY at Forefront of Hepatitis C Elimination Efforts in the US

July 27, 2018
Chad Cipiti

In major step forward, New York State Governor Andrew Cuomo delivered on his earlier commitment to eliminate hepatitis C virus (HCV) with today’s announcement of his intention to appoint a statewide Hepatitis C Elimination Task Force.

Migrants’ Inclusion Central to Achieving HIV and Hepatitis C Targets by 2030

July 26, 2018
Chad Cipiti

The European African Treatment Advocates Network (EATAN), in partnership with Treatment Action Group (TAG) and other migrant-focused organizations, hosted the European African HIV & Hepatitis C Virus (HCV) Community Summit 2018.

White House and Congress Must Boldly Address Drug Pricing and Ensure Access to Critical HIV, HCV, and TB Medications

July 16, 2018
Chad Cipiti

Treatment Action Group (TAG), NASTAD (National Alliance of State & Territorial AIDS Directors) and HIVMA (HIV Medicine Association join together in submitting collaborative comments today in response to the Department of Health and Human Services (HHS) public request for information (RFI) on the agency’s Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs.

TAGline Spring 2018

April 10, 2018
Chad Cipiti

Bend the Curves: Incremental change—activism that successfully defends or advances critical research or policy—can sometimes feel inconsequential, particularly when it is hard won, resource intensive, and intangible.